PolyPid Ltd. (PYPD) is an Israeli clinical-stage biopharmaceutical company developing long-acting, locally administered therapies on its Kynatrix controlled-release platform. Its lead asset, D-PLEX100, delivers doxycycline directly into the surgical wound for about 30 days to prevent surgical site infections following colorectal procedures, and its new drug application is currently under FDA priority review.
The stock traded at $6.48 Tuesday afternoon, up $0.33, or 5.37%, from the prior session's close of $6.15, having ranged between roughly $6.12 and $6.57 during the day. Direction was clearly to the upside. No company-specific announcement or verified news item was found to explain the gain, and the most plausible interpretation is that buyers are positioning ahead of the imminent regulatory decision rather than reacting to new information.
No verified news or fundamental catalyst found for Tuesday's session. The company issued no press release, filed no material disclosure, and drew no new analyst action. The most recent hard catalysts - third-quarter results on Nov. 11 and a Roth Capital price-target increase to $8.50 from $8 the following morning - were already reflected in the move to a $7.15 record on Nov. 11 and the subsequent pullback. That leaves the Nov. 28 PDUFA goal date as the dominant, already-known variable, and buying into a binary regulatory event is a common pattern in small-cap biotechnology.
The price action is also consistent with a short-term technical rebound after three straight declines totaling about 7% from $6.60 to $6.15. With a thin order book typical of a roughly $137 million market capitalization name, modest incremental demand moves the quote disproportionately. Volume of roughly 740,000 shares by mid-afternoon suggests genuine interest rather than a single stray print.
The gain was idiosyncratic. The SPDR S&P Biotech ETF (XBI) slipped about 0.6% and the iShares Biotechnology ETF (IBB) fell a similar amount, while the small-cap Russell 2000 proxy (IWM) dropped roughly 1.5%. PolyPid therefore outperformed its sector and the broad tape by a wide margin, reinforcing the view that the move was event-driven rather than sympathy buying.
Turnover was elevated at more than three times the recent average, a meaningful signal in a name that often trades in the low hundreds of thousands of shares. Technically, the stock defended the $6.03-$6.05 area that held on Friday and Monday, and pushed back toward the $6.57 intraday high. It remains below the Nov. 11 record of $7.15, a level that now acts as the nearest resistance.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. PolyPid scores 14 out of 100.
No verified news was found, so the fundamental component is minimal. The price component is also modest: Tuesday's 5.37% advance was about 2.2 times the stock's average absolute daily change of roughly 2.4% across the past 80 sessions, and five sessions in the last 60 produced moves of comparable or larger size. A routine pre-catalyst drift combined with a familiar-sized swing produces a low score.
The FDA's decision on D-PLEX100 is due by Nov. 28, and labeling discussions with the agency are described as underway, with all scheduled interactions reported on track. Approval would trigger the next milestone payment from U.S. partner Azurity Pharmaceuticals, which has already paid $30 million and is preparing an early-2027 launch targeting more than 1,700 hospitals.
Beyond the decision, investors will watch the label's scope, disclosure of launch pricing, submission progress for broader abdominal indications, the European Medicines Agency review expected in the second half of 2027, and a CMS new technology add-on payment decision slated for August 2027. Fourth-quarter results are expected in February. Key risks include a complete response letter or delay, pre-approval inspection findings, a slower account-by-account hospital rollout, reimbursement uncertainty, and potential dilution given a cash runway the company projects into 2028.
Tickeron's Trending AI Robots page curates the automated strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only a select group is featured here based on live results. Bots differ widely by strategy logic, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as conditions change. Reviewing the curated list is a practical way to see which approaches are working right now and to compare them against your own watchlist.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PYPD's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator showed a similar pattern. In 103 of the 115 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PYPD as a result. In 113 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PYPD just turned positive on October 22, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.
PYPD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PYPD crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in 179 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The 10-day RSI Indicator for PYPD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 16 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 49 cases where PYPD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
PYPD broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.147) is normal, around the industry mean (3.592). P/E Ratio (-4.687) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
Industry Biotechnology